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Abstract
Introduction: Angiomyofibroblastoma is a benign, rare mesenchymal tumor arising from the genital tract of both
men and women and was first described by Fletcher and colleagues in 1992. The tumor needs to be distinguished
from other, similar lesions, such as deep and superficial aggressive angiomyxoma and cellular angiofibroma,
because aggressive angiomyxoma demands much more extensive treatment. The vast majority of
angiomyofibroblastomas arise from the vulva and appear as solid cystic masses on ultrasound images.
Case presentation: We report a case of a 35-year-old Caucasian woman with an angiomyofibroblastoma arising
from the vagina. She presented with a painless mass of about 5cm in diameter that had a rather homogeneous,
hypoechoic appearance on ultrasound images. The patient underwent surgical resection of the mass, which was
subsequently diagnosed as angiomyofibroblastoma. We present sonographic and magnetic resonance imaging
findings, intraoperative and histologic images, and a thorough review of the literature.
Conclusions: In our opinion, ultrasonography is the most valuable tool to establish a preoperative diagnosis of this
tumor entity, differentiate it from other lesions of the female genital tract, and plan surgery accordingly. Even
though it is a rare tumor, gynecologists should be able to recognize it and to differentiate it from other tumor
entities that demand more aggressive treatment. We describe a different sonographic appearance of this tumor
than previously reported.
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Introduction
Angiomyofibroblastoma (AMFB) was first described
by Fletcher and colleagues in 1992 as a distinct sub-
group of mesenchymal tumors histologically similar to
aggressive angiomyoma (AA) that usually arise from
the genital tract in both men and women [1]. The
vast majority of cases originate from the vulva (Fig. 4a).
One case of AMFB in the nasal cavity has been described
recently [2].
In contrast to AA, which is characterized by local de-
structive growth and recurrence after clear margin resec-
tion in up to 47% of cases [3–5], AMFB has an excellent
prognosis. Clinically, the tumor has well-circumscribed
margins, a size of usually about 5cm at the time of diagno-
sis, and virtually no tendency for local recurrence after ex-
cision. Histologically, these tumors are characterized as
being composed of plump, ovoid, or, less often, spindle-
shaped cells, with limited eosinophilic cytoplasm and
ovoid nuclei [1, 6]. Characteristically, the stroma contains
many capillary-sized blood vessels, around which the
characteristic cells aggregate [6].
Together with cellular angiofibroma (CA) and myofi-
broblastoma (MFB), AMFB belongs to a group of benign
stromal tumors of the lower female genital tract. These
tumors, along with AA, have significant overlap in their
morphological and immunohistochemical characteristics,
which can pose serious diagnostic problems [7]. Recent
research, however, has shown that a common cytogenetic
aberration present in angiofibroma (AF) and MFB (loss of* Correspondence: benjamin.wolf@medizin.uni-leipzig.de
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the 13q14 region) is not shared by AMFB, suggesting that
AMFB is not genetically related to AF and MFB [7].
Case presentation
A 35-year-old Caucasian woman was referred to our out-
patient clinic for evaluation of a neoplastic lesion located
adjacent to the uterine cervix. She reported not having ex-
perienced any pain or discomfort with regard to the lesion
and that she had not noticed any changes in bladder or
bowel function. The lesion had come to her gynecologist’s
attention during a routine pelvic examination 1 week earl-
ier. Her history was remarkable for the excision of a melan-
oma from her right inner thigh about 4 years earlier. Two
inguinal lymph nodes that were excised for sentinel staging
at the time were reportedly without metastasis.
In her gynecological examination at our clinic, no in-
guinal lymph node swelling was noted, and her vulva
and proximal vagina appeared normal. The vaginal mu-
cosa on the right side of the posterior fornix was bulging
inward, displacing the uterine cervix laterally to the left.
Underlying the mucosa was a palpable, semimobile mass
of about 5cm in diameter that was of plump, elastic
consistency. The vaginal mucosa overlying the tumor
was smooth but not mobile relative to the tumor. There
were no signs of ulceration or retraction by the tumor.
Sonographically, the mass appeared homogeneous
with medium echogenicity, few septations, and smooth
edges (Fig. 1), and it had no papillary projections. Color
Doppler imaging revealed several vessels visible within
the structure. Subsequently, we took a core biopsy speci-
men of the tumor while the patient was under general
anesthesia. A pathological examination revealed a mes-
enchymal tumor, most probably benign owing to the ab-
sence of any mitotic figures; however, it was not possible
to classify the tumor any further. We discussed the find-
ings with the patient and recommended surgical excision
of the tumor. Owing to the unusual location of the
tumor, we obtained additional magnetic resonance (MR)
images of the pelvis (Fig. 2). T1- and T2-weighted im-
ages showed a homogeneously hypointense lesion that
led to deviation of the cervix and the rectum. For exci-
sion, we performed a horizontal colpotomy about 1.5cm
Fig. 1 a Transvaginal ultrasound image shows a well-demarcated,
homogeneous mass of medium echogenicity (sagittal view). Intralesional
septations can be seen only in Additional file 1. b Color Doppler imaging
reveals intralesional vascularization
Fig. 2 Coronal (a) and sagittal (b) T2-weighted magnetic resonance
images obtained preoperatively show a homogeneous solid mass (T)
displacing the cervix at left (seen best in coronal view)
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distant from the cervix, including the biopsy canal. The
tumor appeared encapsulated and was dissected from
the surrounding tissue. Gross examination of the tumor
showed a 9×6×1.5-cm pinkish gray mass weighing 65g.
The tumor was covered entirely with a frail, well-
vascularized membrane (Fig. 3a).
Histologically, the highly cellular lesion represented vary-
ing cellularity with vascularization by thin-walled blood ves-
sels surrounded by spindle-shaped epithelioid cells with
abundant eosinophilic cytoplasm and positive immuno-
staining for desmin and estrogen receptor (Fig. 3c, d).
The mesenchymal cells showed a diffusely positive
reaction to CD34, and 70% stained positive for desmin.
There was no staining reaction to smooth muscle actin
and S100. About 90% of the cells were estrogen receptor–
positive. On the basis of these characteristics, a diagnosis
of AMFB was made.
At her follow-up examination 17 months postopera-
tively, the patient was doing well and without any evidence
of recurrent disease or sexual or urinary dysfunction.
Discussion
Including our patient, 137 cases of AMFB have been re-
ported to date (for a detailed list, see Additional file 2).
The median age of all patients at the time of presenta-
tion was 45 years (Fig. 4b), the majority of the patients
Fig. 3 a and b Intraoperative appearance of the tumor. The tumor was covered entirely with a frail membrane of pinkish gray appearance.
c Cellular mesenchymal lesion with alternating cellularity intermingled with small blood vessels [hematoxylin and eosin (H&E) stain, original
magnification ×109]. d Higher-magnification image representing thin-walled blood vessels surrounded by ovoid to spindle-shaped cells with
some epithelioid appearance and abundant eosinophilic cytoplasm (H&E stain, original magnification ×241). e Immunohistochemical staining for
desmin with weak positivity. f Strong nuclear expression of estrogen receptor.
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had been aware of their tumors for about 1 year. No re-
currences have been reported after excision, although it
has to be pointed out that the median follow-up of all
cases published thus far is only 12 months. (Information
about follow-up was available for only 64% of published
case reports; see Additional file 2). Only one case of sar-
comatous transformation has been reported; however,
there was no recurrence after resection in that patient
[8]. We found the female-to-male ratio to be 10:1. In
women, the vast majority of tumors are located in the
vulva (Fig. 4a). Owing to their low frequency, AMFBs
and other vaginal soft tissue tumors can easily be con-
fused clinically or sonographically with other, more com-
mon vaginal masses, such as Bartholin’s cyst, rectocele,
or urethral diverticulum [6, 9–11]. However, soft tissue
tumors can be differentiated from these masses by
demonstrating intralesional vascularization using color
Doppler imaging. Once this has been accomplished,
echogenicity and demarcation of the tumor can help to
further establish the diagnosis.
Sonographically, AMFB has been reported to be well
demarcated with inhomogeneous echogenicity and mul-
tiple hypoechoic areas within an echogenic stroma [12].
Wang and coworkers assessed 72 perineal tumors, two
among which represented AMFB and were characterized
as solid cystic masses on the basis of ultrasonography
[13]. In contrast to these descriptions, we found the
tumor in our patient to be of homogeneous, medium
echogenicity without solid cystic features (see Additional
file 1). Retrospectively, the obtained MR images did not
add much information to what was already known based
on the ultrasound studies.
To date, the exact pathogenesis of AMFB is not clear.
Because many tumors express estrogen and progester-
one receptors, it is likely that these hormones play a cru-
cial role in the pathogenesis of AMFB. Indeed, these
tumors almost exclusively occur in women of reproduct-
ive age; two cases of postmenopausal women receiving
tamoxifen therapy have been reported [14, 15]. Because
many of the histological and immunohistochemical fea-
tures of AMFB, AA, and CA overlap, it has been sug-
gested that these richly vascularized myxoid tumors of the
genital tract represent members of the same fibroblastic–
myofibroblastic tumor spectrum [16]. Sonography is a
widely available, relatively cheap, extremely valuable tool
to characterize and distinguish these tumors preopera-
tively and to plan surgery accordingly. In our opinion, MR
imaging is not mandatory in the evaluation of soft tissue
lesions of the lower genital tract such as AMFB in women.
Postoperative pathological examination of the surgical
specimen remains the only way to definitively establish a
diagnosis of AMFB.
Conclusions
AMFB is a rare, benign stromal tumor arising most
commonly from the female lower reproductive tract, and
ultrasonography is the most important imaging modality
in its preoperative diagnosis and management. AMFB
appears as a homogeneous, well-defined, vascularized le-
sion of medium echogenicity. AMFB needs to be distin-
guished from aggressive angiomyxoma because the latter
demands more extensive treatment.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Fig. 4 Analysis of all 125 cases of angiomyofibroblastoma in women
reported to date (see also Additional file 2). a The number of cases of
angiomyofibroblastoma occurring at each given location out of a total of
125 cases is shown. *N/A denotes that no information regarding the
location was available. **Other locations include inguinal, urethral,
fallopian tube, perianal, cul-de-sac, and retroperitoneal. b Histogram
showing the age distribution of 116 patients with angiomyofibroblastoma
(including men). For 21 patients, no age information was available for
analysis. AMFB angiomyofibroblastoma
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Additional files
Additional file 1: Ultrasonographic appearance of AMFB. Collection of
short ultrasound clips showing the characteristics of AMFB. (WMV 11397 kb)
Additional file 2: Published case reports of AMFB up to the time of
the writing of this report. (XLSX 21 kb)
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